Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
analgesic
|
| gptkbp:clinical_trial |
Phase III
Ziconotide for Pain Management |
| gptkbp:clinical_use |
severe pain
|
| gptkbp:condition |
neuropathic pain
cancer pain post-surgical pain multiple sclerosis pain spinal cord injury pain |
| gptkbp:contraindication |
hypersensitivity to ziconotide
|
| gptkbp:dosage_form |
gptkb:Software_Solutions
|
| gptkbp:drug_interactions |
CNS depressants
antihypertensives opioids |
| gptkbp:duration |
as needed
|
| gptkbp:formulation |
intrathecal infusion
|
| https://www.w3.org/2000/01/rdf-schema#label |
Prialt
|
| gptkbp:ingredients |
gptkb:ziconotide
|
| gptkbp:invention |
2024
patented |
| gptkbp:manufacturer |
gptkb:Elan_Pharmaceuticals
|
| gptkbp:marketed_as |
gptkb:Prialt
|
| gptkbp:mechanism_of_action |
N-type calcium channel blocker
|
| gptkbp:packaging |
single-use vial
|
| gptkbp:patient_population |
adults
|
| gptkbp:price |
varies by pharmacy
|
| gptkbp:provides_guidance_on |
recommended for refractory pain
|
| gptkbp:research_focus |
neurology
pharmacology drug delivery systems pain management chronic pain syndromes |
| gptkbp:route_of_administration |
intrathecal
pump delivery system |
| gptkbp:safety_measures |
risk of severe neurological impairment
not for use in patients with pre-existing neurological conditions |
| gptkbp:service_frequency |
daily
|
| gptkbp:side_effect |
dizziness
headache nausea confusion gastrointestinal disturbances injection site reactions psychological effects urinary retention somnolence cardiovascular effects |
| gptkbp:storage |
refrigerated
|
| gptkbp:treatment |
improved quality of life
pain relief patient satisfaction functional improvement reduced opioid use |
| gptkbp:used_for |
chronic pain management
|
| gptkbp:bfsParent |
gptkb:Elan_Corporation
|
| gptkbp:bfsLayer |
6
|